Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2011 (2011), Article ID 751671, 6 pages
http://dx.doi.org/10.1155/2011/751671
Research Article

Different Influences on Tacrolimus Pharmacokinetics by Coadministrations of Zhi Ke and Zhi Shi in Rats

1School of Pharmacy, China Medical University, Taichung 40402, Taiwan
2School of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 40402, Taiwan
3Institute of Athletics, National Taiwan College of Physical Education, Taichung 40404, Taiwan

Received 12 July 2010; Revised 19 October 2010; Accepted 28 December 2010

Copyright © 2011 Shiuan-Pey Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Chinese Pharmacopoeia Commission, The Pharmacopoeia of the People’s Republic of China, Chemical Industry Press, Beijing, China, 2000.
  2. Y. S. Wang and W. Y. Luo, “Studies on quantitative determination of total flavonoid in qingpi, zhiqiao and zhishi by TLC-densitometric methods,” Zhongguo Zhong Yao Za Zhi, vol. 14, no. 4, pp. 230–255, 1989. View at Google Scholar · View at Scopus
  3. F. Pellati, S. Benvenuti, and M. Melegari, “High-performance liquid chromatography methods for the analysis of adrenergic amines and flavanones in Citrus aurantium L. var. amara,” Phytochemical Analysis, vol. 15, no. 4, pp. 220–225, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Venkataramanan, A. Jain, E. Cadoff et al., “Pharmacokinetics of FK 506: preclinical and clinical studies,” Transplantation Proceedings, vol. 22, no. 1, pp. 52–56, 1990. View at Google Scholar · View at Scopus
  5. R. P. Kershner and W. E. Fitzsimmons, “Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation,” Transplantation, vol. 62, no. 7, pp. 920–926, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Nakata, M. Yoshibayashi, T. Yonemura et al., “Tacrolimus and myocardial hypertrophy,” Transplantation, vol. 69, no. 9, pp. 1960–1962, 2000. View at Google Scholar · View at Scopus
  7. J. M. Morales, A. Andres, M. Rengel, and J. L. Rodicio, “Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation,” Nephrology Dialysis Transplantation, vol. 16, supplement 1, pp. 121–124, 2001. View at Google Scholar
  8. R. Higgins, K. Ramaiyan, T. Dasgupta et al., “Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities,” Nephrology Dialysis Transplantation, vol. 19, no. 2, pp. 444–450, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Y. Chenhsu, C. C. Loong, M. H. Chou, M. F. Lin, and WU. C. Yang, “Renal allograft dysfunction associated with rifampin-tacrolimus interaction,” Annals of Pharmacotherapy, vol. 34, no. 1, pp. 27–31, 2000. View at Google Scholar · View at Scopus
  10. F. Ruschitzka, P. J. Meier, M. Turina, T. F. Lüscher, and G. Noll, “Acute heart transplant rejection due to Saint John's wort,” Lancet, vol. 355, no. 9203, pp. 548–549, 2000. View at Google Scholar · View at Scopus
  11. T. Saeki, K. Ueda, Y. Tanigawara, R. Hori, and T. Komano, “Human P-glycoprotein transports cyclosporin A and FK506,” Journal of Biological Chemistry, vol. 268, no. 9, pp. 6077–6080, 1993. View at Google Scholar · View at Scopus
  12. J. N. Roy, A. Barama, C. Poirier, B. Vinet, and M. Roger, “Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients,” Pharmacogenetics and Genomics, vol. 16, no. 9, pp. 659–665, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. K. N. Utecht, J. J. Hiles, and J. Kolesar, “Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors,” American Journal of Health-System Pharmacy, vol. 63, no. 23, pp. 2340–2348, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. G. K. Dresser and D. G. Bailey, “The effects of fruit juices on drug disposition: a new model for drug interactions,” European Journal of Clinical Investigation, vol. 33, no. 2, pp. 10–16, 2003. View at Google Scholar · View at Scopus
  15. K. Egashira, E. Fukuda, T. Onga et al., “Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient,” Transplantation, vol. 75, no. 7, p. 1057, 2003. View at Google Scholar · View at Scopus
  16. K. Egashira, H. Ohtani, S. Itoh et al., “Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein,” Drug Metabolism and Disposition, vol. 32, no. 8, pp. 828–833, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Fukatsu, M. Fukudo, S. Masuda et al., “Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient,” Drug metabolism and pharmacokinetics, vol. 21, no. 2, pp. 122–125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Liu, Y. F. Shang, X. F. Zhang et al., “Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study,” European Journal of Clinical Pharmacology, vol. 65, no. 9, pp. 881–885, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. C. Hou, S. L. Hsiu, C. W. Tsao, Y. H. Wang, and P. D. L. Chao, “Acute intoxication of cyclosporin caused by coadministration of decoctions of the fruits of Citrus aurantium and the pericarps of Citrus grandis,” Planta Medica, vol. 66, no. 7, pp. 653–655, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. M. J. Wang, Y. C. Hou, S. Y. Tsai, S. L. Hsiu, K. C. Wen, and P. D. L. Chao, “Effects of coadministrations of unripe fruits and ripe peels of Citrus aurantium on cyclosporine pharmacokinetics in rats,” Journal of Food and Drug Analysis, vol. 15, no. 3, pp. 265–270, 2007. View at Google Scholar · View at Scopus
  21. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at Google Scholar · View at Scopus
  22. J. X. Jia and K. M. Wasan, “Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-D-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells,” Journal of Pharmacy & Pharmaceutical Sciences, vol. 11, no. 3, pp. 45–62, 2008. View at Google Scholar
  23. C. Bistrup, F. T. Nielsen, U. E. Jeppesen, and H. Dieperink, “Effect of grapefruit juice on Sandimmum Neoral® absorption among stable renal allograft recipients,” Nephrology Dialysis Transplantation, vol. 16, no. 2, pp. 373–377, 2001. View at Google Scholar · View at Scopus
  24. U. Christians, W. Jacobsen, L. Z. Benet, and A. Lampen, “Mechanisms of clinically relevant drug interactions associated with tacrolimus,” Clinical Pharmacokinetics, vol. 41, no. 11, pp. 813–851, 2002. View at Google Scholar · View at Scopus
  25. M. Saito, M. Hirata-Koizumi, M. Matsumoto, T. Urano, and R. Hasegawa, “Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies,” Drug Safety, vol. 28, no. 8, pp. 677–694, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. D. J. Edwards, F. H. Bellevue III, and P. M. Woster, “Identification of 6,7-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice,” Drug Metabolism and Disposition, vol. 24, no. 12, pp. 1287–1290, 1996. View at Google Scholar · View at Scopus
  27. K. He, K. R. Iyer, R. N. Hayes, M. W. Sinz, T. F. Woolf, and P. F. Hollenberg, “Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice,” Chemical Research in Toxicology, vol. 11, no. 4, pp. 252–259, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Lian-Qing, K. Fukuda, T. Ohta, and Y. Yamazoe, “Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity,” Drug Metabolism and Disposition, vol. 28, no. 7, pp. 766–771, 2000. View at Google Scholar · View at Scopus
  29. A. Ohnishi, H. Matsuo, S. Yamada et al., “Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4,” British Journal of Pharmacology, vol. 130, no. 6, pp. 1369–1377, 2000. View at Google Scholar
  30. W. Tassaneeyakul, L.-Q. Guo, K. Fukuda, T. Ohta, and Y. Yamazoe, “Inhibition selectivity of grapefruit juice components on human cytochromes P450,” Archives of Biochemistry and Biophysics, vol. 378, no. 2, pp. 356–363, 2000. View at Publisher · View at Google Scholar
  31. P.-C. Ho, D. J. Saville, and S. Wanwimolruk, “Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 4, no. 3, pp. 217–227, 2001. View at Google Scholar
  32. Y. Honda, F. Ushigome, N. Koyabu et al., “Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux,” British Journal of Pharmacology, vol. 143, no. 7, pp. 856–864, 2004. View at Publisher · View at Google Scholar
  33. M. F. Paine, W. W. Widmer, H. L. Hart et al., “A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction,” American Journal of Clinical Nutrition, vol. 83, no. 5, pp. 1097–1105, 2006. View at Google Scholar · View at Scopus
  34. K. S. Lown, D. G. Bailey, R. J. Fontana et al., “Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression,” Journal of Clinical Investigation, vol. 99, no. 10, pp. 2545–2553, 1997. View at Google Scholar · View at Scopus
  35. P. Schmiedlin-Ren, D. J. Edwards, M. E. Fitzsimmons et al., “Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins,” Drug Metabolism and Disposition, vol. 25, no. 11, pp. 1228–1233, 1997. View at Google Scholar · View at Scopus
  36. G. C. Kane and J. J. Lipsky, “Drug-grapefruit juice interactions,” Mayo Clinic Proceedings, vol. 75, no. 9, pp. 933–942, 2000. View at Google Scholar · View at Scopus
  37. L. Q. Guo, M. Taniguchi, Q. Y. Chen, K. Baba, and Y. Yamazoe, “Inhibitory potential of herbal medicines on human cytochrome P450-mediated oxidation: properties of Umbelliferous or Citrus crude drugs and their relative prescriptions,” Japanese Journal of Pharmacology, vol. 85, no. 4, pp. 399–408, 2001. View at Publisher · View at Google Scholar · View at Scopus